Results 81 to 90 of about 8,218,774 (258)

Clinical implications of combined glucose intolerance in treatment-naïve hypertensive patients

open access: yesClinical and Experimental Hypertension, 2018
Background: This study is the first study to evaluate clinical significance of combined glucose intolerance (CGI) in treatment-naïve hypertensive patients. Methods: We compared the results of demographic, anthropometric, clinical, laboratory examinations,
Beom-June Kwon   +8 more
doaj   +1 more source

Association of glucose tolerance status with pancreatic β‐ and α‐cell mass in community‐based autopsy samples of Japanese individuals: The Hisayama Study

open access: yesJournal of Diabetes Investigation, 2020
Aims/Introduction Changes in histologically quantified β‐ and α‐cell mass during the development of glucose intolerance have not been fully elucidated. The aim of the present study was to explore differences in β‐ and α‐cell mass according to the glucose
Jun Inaishi   +9 more
doaj   +1 more source

Microfluidic Engineering of Microgels: A Review of Emerging Technologies, Materials, Fabrication Strategies, and Applications

open access: yesAdvanced Healthcare Materials, EarlyView.
Recent advances in microfluidic technologies for microgel fabrication are critically reviewed, highlighting the capabilities and limitations of major microfluidic platforms and discussing how platform design, material selection, and crosslinking strategies influence microgel architecture and functionality. Current challenges and future opportunities in
Afshin Abrishamkar   +6 more
wiley   +1 more source

Impact of glucose excursion and mean glucose concentration in oral glucose-tolerance test on oxidative stress among Japanese Americans

open access: yes, 2013
Shuhei Nakanishi, Masayasu Yoneda, Shusaku Maeda Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan Aim: To evaluate the impact of glucose excursion (GE) and mean ...
Maeda S, Yoneda M, Nakanishi S
core  

Body weight, glucose tolerance test and insulin tolerance test in HFD rats and control rats.

open access: yes, 2014
(A) Body weight curves for Wistar rats fed on a standard rodent chow diet (control) or a high-fat diet (HFD) starting at 4 weeks of age. (B) Glucose tolerance test. (C) Insulin tolerance test. The baseline glucose levels are 5.5±0.3 mmol/L in control and
Yuan-yuan Liu (2575882)   +7 more
core   +1 more source

Area under the curve (AUC) and Cmax in glucose tolerance test.

open access: yes, 2022
Area under the curve (AUC) and Cmax in glucose tolerance test.
Annalise Di Marco (8611002)   +7 more
core   +1 more source

An Antimicrobial, Cell‐Adhesive, and Growth Factor‐Producing Living Material Engineered From Bacillus subtilis Biofilms for Wound Healing

open access: yesAdvanced Healthcare Materials, EarlyView.
Bacillus subtilis is engineered to produce cell‐adhesive biofilms by functionalization of its biofilm scaffold protein TasA with a cell‐adhesion sequence. Living bacteria within the biofilm are also engineered to secrete growth factors and natively produce antimicrobial peptides (AMPs), resulting in a cell‐adhesive, antimicrobial, and growth factor ...
Mélanie Côté‐Cyr   +3 more
wiley   +1 more source

Role of HbA1c in post-partum screening of women with gestational diabetes mellitus

open access: yesJournal of Clinical & Translational Endocrinology, 2015
Aim: To compare the performance of HbA1c with established glucose criteria during an oral glucose tolerance test (OGTT) and to assess HbA1c as a screening test for undiagnosed diabetes and pre-diabetes after gestational diabetes mellitus (GDM).
Rickard Claesson   +3 more
doaj   +1 more source

Fasting plasma glucose, or 2-hour post 75-g oral glucose tolerance test, or hemoglobin HbA1c by age group.

open access: yes, 2018
Fasting plasma glucose, or 2-hour post 75-g oral glucose tolerance test, or hemoglobin HbA1c by age group.
Jose Lopez-Lopez (5100482)   +6 more
core   +1 more source

Modeling Early Metastatic Progression in Breast Cancer Using a Barrier‐Free, Perfusable Spheroid‐on‐a‐Chip Platform

open access: yesAdvanced Healthcare Materials, EarlyView.
Open‐port, barrier‐free microfluidic device for modeling early metastatic progression. A centrally positioned tumor spheroid releases invasive cells that migrate through the surrounding matrix and intravasate into endothelialized lateral channels.
Vira Sharko   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy